Risk Assessment of Drug‐Induced Long QT Syndrome for Some COVID‐19 Repurposed Drugs

• Hauptverfasser: Veronique Michaud (Verfasst von), Pamela Dow (Verfasst von), Sweilem B. Al Rihani (Verfasst von), Malavika Deodhar (Verfasst von), Meghan Arwood (Verfasst von), Brian Cicali (Verfasst von), Jacques Turgeon (Verfasst von)
• Format: Buch
• Veröffentlicht: Wiley, 2021-01-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

The risk‐benefit ratio associated with the use of repurposed drugs to treat severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2)‐related infectious coronavirus disease 2019 (COVID‐19) is complicated because benefits are awaited, not proven. A thorough literature search was conducted to sourc...